141 related articles for article (PubMed ID: 38429995)
1. Combining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically significant prostate cancer.
Plym A; Madueke I; Naik S; Isabelle M; Conti DV; Haiman CA; Penney KL; Mucci LA; Khorasani R; Kibel AS
JNCI Cancer Spectr; 2024 Feb; 8(2):. PubMed ID: 38429995
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.
Cussenot O; Renard-Penna R; Montagne S; Ondet V; Pilon A; Guechot J; Comperat E; Hamdy F; Lamb A; Cancel-Tassin G
BJU Int; 2023 Jun; 131(6):745-754. PubMed ID: 36648168
[TBL] [Abstract][Full Text] [Related]
4. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations.
Chen F; Darst BF; Madduri RK; Rodriguez AA; Sheng X; Rentsch CT; Andrews C; Tang W; Kibel AS; Plym A; Cho K; Jalloh M; Gueye SM; Niang L; Ogunbiyi OJ; Popoola O; Adebiyi AO; Aisuodionoe-Shadrach OI; Ajibola HO; Jamda MA; Oluwole OP; Nwegbu M; Adusei B; Mante S; Darkwa-Abrahams A; Mensah JE; Adjei AA; Diop H; Lachance J; Rebbeck TR; Ambs S; Gaziano JM; Justice AC; Conti DV; Haiman CA
Elife; 2022 Jul; 11():. PubMed ID: 35801699
[TBL] [Abstract][Full Text] [Related]
5. Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
Patel HD; Koehne EL; Shea SM; Bhanji Y; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Gupta GN
Cancer; 2022 Jan; 128(1):75-84. PubMed ID: 34427930
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
8. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
9. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
Johnson DC; Raman SS; Mirak SA; Kwan L; Bajgiran AM; Hsu W; Maehara CK; Ahuja P; Faiena I; Pooli A; Salmasi A; Sisk A; Felker ER; Lu DSK; Reiter RE
Eur Urol; 2019 May; 75(5):712-720. PubMed ID: 30509763
[TBL] [Abstract][Full Text] [Related]
10. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic pathway of the biopsy-naïve patient suspected for prostate cancer: Real-life scenario when multiparametric Magnetic Resonance Imaging is not centralized.
Bertolo R; Vittori M; Cipriani C; Maiorino F; Forte V; Iacovelli V; Petta F; Sperandio M; Marani C; Panei M; Travaglia S; Bove P
Prog Urol; 2021 Oct; 31(12):739-746. PubMed ID: 33431200
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
13. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
[TBL] [Abstract][Full Text] [Related]
14. Ruling out clinically significant prostate cancer with negative multi-parametric MRI.
An JY; Sidana A; Holzman SA; Baiocco JA; Mehralivand S; Choyke PL; Wood BJ; Turkbey B; Pinto PA
Int Urol Nephrol; 2018 Jan; 50(1):7-12. PubMed ID: 29143253
[TBL] [Abstract][Full Text] [Related]
15. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
[TBL] [Abstract][Full Text] [Related]
16. The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.
Gnanapragasam VJ; Burling K; George A; Stearn S; Warren A; Barrett T; Koo B; Gallagher FA; Doble A; Kastner C; Parker RA
Sci Rep; 2016 Oct; 6():35364. PubMed ID: 27748407
[TBL] [Abstract][Full Text] [Related]
17. The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy.
Kotb AF; Spaner S; Crump T; Hyndman ME
World J Urol; 2018 Dec; 36(12):2021-2025. PubMed ID: 29808301
[TBL] [Abstract][Full Text] [Related]
18. Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway.
Wiemer L; Hollenbach M; Heckmann R; Kittner B; Plage H; Reimann M; Asbach P; Friedersdorff F; Schlomm T; Hofbauer S; Cash H
Eur Urol Focus; 2021 Nov; 7(6):1292-1299. PubMed ID: 32654967
[TBL] [Abstract][Full Text] [Related]
19. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy.
Simmons LAM; Kanthabalan A; Arya M; Briggs T; Barratt D; Charman SC; Freeman A; Gelister J; Hawkes D; Hu Y; Jameson C; McCartan N; Moore CM; Punwani S; Ramachandran N; van der Meulen J; Emberton M; Ahmed HU
Br J Cancer; 2017 Apr; 116(9):1159-1165. PubMed ID: 28350785
[TBL] [Abstract][Full Text] [Related]
20. A prospective study investigating the impact of multiparametric MRI in biopsy-naïve patients with clinically suspected prostate cancer: The PROKOMB study.
Baur ADJ; Henkel T; Johannsen M; Speck T; Weißbach L; Hamm B; König F
Contemp Clin Trials; 2017 May; 56():46-51. PubMed ID: 28279782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
